Sources & References

[1] Vahratian A, Lin JMS, Bertolli J, Unger ER. "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021-2022." NCHS Data Brief No. 488. CDC National Center for Health Statistics. December 8, 2023. cdc.gov/nchs/products/databriefs/db488.htm

[2] CDC. "ME/CFS Basics." Centers for Disease Control and Prevention. Updated May 2024. cdc.gov/me-cfs/about/index.html

[3] Committee on the Diagnostic Criteria for ME/CFS; Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press. 2015. doi:10.17226/19012

[4] Morita S, Tokumasu K, Otsuka Y, et al. "Phase-dependent trends in the prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) related to long COVID: A criteria-based retrospective study in Japan." PLOS ONE. 2024;19(12):e0315385. doi:10.1371/journal.pone.0315385 [8.4% of 739 long COVID outpatients met ME/CFS criteria; rate fell from 23.9% (pre-Delta) to 3.3% (Omicron period).] See also: Jason LA, Dorri JA. Neurology International. 2023;15(1):1-11. doi:10.3390/neurolint15010001 [58% of 465 long COVID patients met ME/CFS case definitions]; Vernon SD et al. Journal of General Internal Medicine. April 2025 [NIH RECOVER: 4.5% of 11,785 COVID-19 patients developed ME/CFS vs 0.6% controls; hazard ratio 4.93].

[5] CDC. "IOM 2015 Diagnostic Criteria." ME/CFS Healthcare Provider Resources. Updated May 2024. cdc.gov/me-cfs/hcp/diagnosis

[6] American ME and CFS Society. "How Many People Have ME/CFS?" ammes.org. Citing CDC estimates of 17-24 million worldwide. Infection-related peri-onset events were reported by 64% of patients in: Chu L, Valencia IJ, Garvert DW, Montoya JG. "Onset Patterns and Course of ME/CFS." Frontiers in Pediatrics. 2019. doi:10.3389/fped.2019.00012

[7] Komaroff AL. "Advances in Understanding the Pathophysiology of Chronic Fatigue Syndrome." JAMA. 2019;322(6):499-500. doi:10.1001/jama.2019.8312 [Viewpoint summarising the neurological, metabolic and immunological abnormalities documented in ME/CFS. Note: this paper contains no SF-36 or quality-of-life comparison data.]

[8] Walitt B, Singh K, LaMunion SR, et al. (Nath A, senior author). "Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome." Nature Communications. 2024;15:907. doi:10.1038/s41467-024-45107-3

[9] NINDS/NIH. "ME/CFS Research Roadmap." Presented to NANDS Council, May 15, 2024. Working Group Final Report. ninds.nih.gov

[10] Wang PY, Ma J, Kim YC, et al. (Hwang PM, senior author). "WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome." Proceedings of the National Academy of Sciences. 2023;120(34):e2302738120. doi:10.1073/pnas.2302738120

[11] DecodeME Consortium; Ponting CP, et al. "Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome." medRxiv preprint, posted August 2025. doi:10.1101/2025.08.06.25333109. [Up to 15,579 ME/CFS cases and 259,909 population controls of European genetic ancestry; eight genetic signals associated with ME/CFS, implicating immune and nervous system pathways. Preprint; not yet peer reviewed as of August 2026.] medrxiv.org

[12] Scheibenbogen C, et al. "Autoimmune mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome." ME/CFS Research Foundation MRR publications. 2024. See also: Scheibenbogen C, Loebel M, Freitag H, et al. "Immunoadsorption to remove beta2-adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME." PLOS ONE. 2018;13(3):e0193672. doi:10.1371/journal.pone.0193672

[13] Klimas NG, Koneru AO. "Chronic fatigue syndrome: inflammation, immune function, and neuroendocrine interactions." Current Rheumatology Reports. 2007;9(6):482-487. [NK cell function-severity correlations; also see Bateman Horne Center clinical resources re: NK cell testing.]

[14] Nakatomi Y, Mizuno K, Ishii A, et al. "Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET Study." Journal of Nuclear Medicine. 2014;55(6):945-950. doi:10.2967/jnumed.113.131045. PMID: 24665088

[15] Walitt B, Singh K, LaMunion SR, et al. Nature Communications. 2024. [See reference 8.]

[16] Natelson BH, Lin JS, Blate M, Khan S, Chen Y, Unger ER. "Physiological assessment of orthostatic intolerance in chronic fatigue syndrome." Journal of Translational Medicine. 2022;20(1):95. doi:10.1186/s12967-022-03289-8

[17] Giannoccaro MP, Donadio V, Incensi A, Avoni P, Liguori R. "Small nerve fiber involvement in patients referred for fibromyalgia." Muscle & Nerve. 2014;49(5):757-759. doi:10.1002/mus.24156. PMID: 24469976. See also: Oaklander AL, Herzog ZD, Downs HM, Klein MM. "Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia." Pain. 2013;154(11):2310-2316. doi:10.1016/j.pain.2013.06.001. PMID: 23811315. [Scope note: both studies examined fibromyalgia cohorts, not ME/CFS cohorts. Fibromyalgia and ME/CFS overlap heavily, with an estimated 35-70% of ME/CFS patients also meeting fibromyalgia criteria, so these findings are widely treated as relevant to ME/CFS. They are not, however, direct evidence in an ME/CFS population. Dedicated small fibre neuropathy studies in ME/CFS cohorts are still needed.]

[18] Saha AK, Schmidt BR, Wilhelmy J, et al. "Red blood cell deformability is diminished in patients with Chronic Fatigue Syndrome." Clinical Hemorheology and Microcirculation. 2019;71(1):113-116. doi:10.3233/CH-180469 [Emerging literature; see also red blood cell rigidity findings cited in RTHM 2024 ME/CFS Research Review: rthm.com]

[19] Pretorius E, et al. "Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin." Cardiovascular Diabetology. 2021. [Microclot findings in long COVID; application to ME/CFS subset is emerging and not yet fully established.]

[20] Giloteaux L, Goodrich JK, Walters WA, et al. "Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome." Microbiome. 2016;4(1):30. doi:10.1186/s40168-016-0171-4

[21] Nagy-Szakal D, Williams BL, Mishra N, et al. "Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome." Microbiome. 2017;5(1):44. doi:10.1186/s40168-017-0261-y

[22] Naviaux RK, Naviaux JC, Li K, et al. "Metabolic features of chronic fatigue syndrome." Proceedings of the National Academy of Sciences. 2016;113(37):E5472-E5480. doi:10.1073/pnas.1607571113

[23] Workwell Foundation. Two-Day Cardiopulmonary Exercise Testing in ME/CFS. See: Keller BA, Pryor JL, Giloteaux L. "Inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO2peak indicates functional impairment." Journal of Translational Medicine. 2014;12:104. doi:10.1186/1479-5876-12-104

[24] Castro-Marrero J, Segundo MJ, Lacasa M, et al. "Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with ME/CFS: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial." Nutrients. 2021;13(8):2658. doi:10.3390/nu13082658. [Note: trial funded in part by supplement manufacturer Vitae Health Innovation; independent reviewers noted small between-group effect sizes.]

[25] Tsai I-C, Hsu C-W, Chang C-H, Tseng P-T, Chang K-V. "Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Frontiers in Pharmacology. 2022;13:883251. doi:10.3389/fphar.2022.883251

[26] Bateman L, Bested AC, Bonilla HF, et al. (U.S. ME/CFS Clinician Coalition). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management." Mayo Clinic Proceedings. 2021;96(11):2861-2878. doi:10.1016/j.mayocp.2021.07.004

[27] Teitelbaum JE, Johnson C, St Cyr J. "The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study." Journal of Alternative and Complementary Medicine. 2006;12(9):857-862. doi:10.1089/acm.2006.12.857. [Open-label, n=41, no control arm; results should be interpreted cautiously.]

[28] Theoharides TC, et al. "Mast cells and inflammation." Biochimica et Biophysica Acta. 2012;1822(1):21-33. [Mechanistic basis for quercetin in mast cell/neuroinflammation contexts.]

[29] Theoharides TC, Asadi S, Patel AB. "Focal brain inflammation and autism." Journal of Neuroinflammation. 2013;10:46. [Preclinical/mechanistic basis for luteolin.]

[30] Pratte MA, Nanavati KB, Young V, Morley CP. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." Journal of Alternative and Complementary Medicine. 2014;20(12):901-908. doi:10.1089/acm.2014.0177

[31] Ishaque S, Shamseer L, Bukutu C, Vohra S. "Rhodiola rosea for physical and mental fatigue: a systematic review." BMC Complementary and Alternative Medicine. 2012;12:70. doi:10.1186/1472-6882-12-70

[32] Ostojic SM. "Molecular hydrogen in sports medicine: new therapeutic perspectives." International Journal of Sports Medicine. 2015;36(4):273-279. doi:10.1055/s-0034-1395509. See also: 2025 review in International Journal of Molecular Sciences on molecular hydrogen and ME/CFS-relevant mechanisms. [Specific 2025 IJMS citation pending full journal publication details.]

[33] U.S. ME/CFS Clinician Coalition. "Testing Recommendations for Suspected ME/CFS." 2021. Available at batemanhornecenter.org. [Includes recognition of MCAS as a relevant comorbidity.]

[34] Hickie I, Davenport T, Wakefield D, et al. "Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study." BMJ. 2006;333(7568):575. doi:10.1136/bmj.38933.585764.AE

[35] Komaroff AL, Bateman L. "Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome?" Frontiers in Medicine. 2021. [Lyme/PTLDS as ME/CFS trigger context.]

[36] Eckey M, Li P, Morrison B, Bergquist J, Davis RW, Xiao W. "Patient-reported treatment outcomes in ME/CFS and long COVID." Proceedings of the National Academy of Sciences. 2025;122(28):e2426874122. doi:10.1073/pnas.2426874122. [3,925 patient survey; symptom subgroups; ME/CFS-long COVID overlap.]

[37] NICE Guideline NG206. "Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management." National Institute for Health and Care Excellence. October 2021. nice.org.uk/guidance/ng206

[38] Fluge O, Mella O, Bruland O, et al. "Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/CFS." JCI Insight. 2016;1(21):e89376. doi:10.1172/jci.insight.89376. [Also: RituxME trial: Fluge O et al. Annals of Internal Medicine. 2019.]

[39] Charite Universitaetsmedizin Berlin (sponsor); Pressler H, Pruss H, et al. "Immunoadsorption in ME/CFS patients with post-COVID CFS (IA-PACS-CFS)." Protocol: Pressler H, et al. Trials. 2024. Trial registration NCT05710770. ClinicalTrials.gov. Registered February 2023. clinicaltrials.gov

[40] Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. "Randomized Trial of Ivabradine in Patients with Hyperadrenergic Postural Orthostatic Tachycardia Syndrome." Journal of the American College of Cardiology. 2021;77(7):861-871. doi:10.1016/j.jacc.2020.12.029

[41] Raj SR, Guzman JC, Harvey P, et al. "Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance." Canadian Journal of Cardiology. 2020;36(3):357-372. doi:10.1016/j.cjca.2019.12.024. [The specific Raj pyridostigmine RCT referenced in text is the 2005 Mayo Clinic study: Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. "Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension." Journal of Neurology, Neurosurgery & Psychiatry. 2003;74(9):1294-1298. doi:10.1136/jnnp.74.9.1294.]

[42] Lewy AJ, Ahmed S, Jackson JML, Sack RL. "Melatonin shifts human circadian rhythms according to a phase-response curve." Chronobiology International. 1992;9(5):380-392. doi:10.3109/07420529209064550. [Establishing low-dose melatonin for circadian phase shifting.]

[43] Tonix Pharmaceuticals. "FDA Approves Tonmya (cyclobenzaprine HCl sublingual tablet, 2.8 mg) for the Management of Fibromyalgia." Press release, August 15, 2025. [Approved for the treatment of fibromyalgia in adults; dosing starts at 2.8 mg and titrates to 5.6 mg. Pivotal evidence: the RELIEF and RESILIENT Phase 3 trials.]

[44] Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradisnik S. "Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment." Frontiers in Immunology. 2021;12:687806. doi:10.3389/fimmu.2021.687806

[45] Blockmans D, Persoons P, Van Houdenhove B, Lejeune M, Bobbaers H. "Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study." American Journal of Medicine. 2003. [Methylphenidate reference: Blockmans D et al. "Does methylphenidate reduce the symptoms of chronic fatigue syndrome?" American Journal of Medicine. 2006;119(2):167.e23-30. doi:10.1016/j.amjmed.2005.07.047]

[46] Hohberger B, Ganslmayer M, Harrer T, et al. "Safety, tolerability and clinical effects of rovunaptabin (BC007) in patients with post-COVID syndrome (reCOVer trial)." eClinicalMedicine. 2025;86:103358. doi:10.1016/j.eclinm.2025.103358. [Peer reviewed and published July 2025. Preprint posted 13 December 2024, doi:10.1101/2024.12.13.24318856.]

[47] AIM ImmunoTech. "Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions." January 2025. [Note: AMP-518 studied post-COVID conditions, not ME/CFS.] Available at aimimmuno.com. [Evidence for rintatolimod has been mixed; the FDA has twice declined to approve it; fast-track designation does not imply efficacy.]

[48] Brattberg G. "Connective tissue massage in the treatment of fibromyalgia." European Journal of Pain. 1999;3(3):235-244. doi:10.1016/S1090-3801(99)90050-2. See also: Systematic review: Kalichman L. "Massage therapy for fibromyalgia symptoms." Rheumatology International. 2010;30(9):1151-1157.

[49] Carson JW, Carson KM, Jones KD, Bennett RM, Wright CL, Mist SD. "A pilot randomized controlled trial of the Yoga of Awareness program in the management of fibromyalgia." Pain. 2010;151(2):530-539. doi:10.1016/j.pain.2010.08.020

[50] Zhang Q, Gong J, Dong H, Xu S, Wang W, Huang G. "Acupuncture for chronic fatigue syndrome: a systematic review and meta-analysis." Acupuncture in Medicine. 2019;37(4):211-222. doi:10.1136/acupmed-2017-011582

[51] Zheng ZS, Simonian N, Wang J, Rosario ER. "Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study." Frontiers in Neurology. 2024;15:1393371. doi:10.3389/fneur.2024.1393371. [Pilot study in a female-only long COVID cohort. ME/CFS-specific RCT evidence is not yet available.]

[52] Wilshire CE, Kindlon T, Courtney R, et al. "Rethinking the treatment of chronic fatigue syndrome - a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT." BMC Psychology. 2018;6(1):6. doi:10.1186/s40359-018-0218-3. [Key methodological critique of the PACE trial's CBT/GET evidence base.]

[53] Klempner MS, Hu LT, Evans J, et al. "Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease." New England Journal of Medicine. 2001;345(2):85-92. doi:10.1056/NEJM200107123450202. [One of three NIH-funded RCTs finding no benefit of prolonged antibiotics in PTLDS.]

[54] Gazit Y, Nahir AM, Grahame R, Jacob G. "Dysautonomia in the joint hypermobility syndrome." American Journal of Medicine. 2003;115(1):33-40. doi:10.1016/s0002-9343(03)00235-3. [48 joint hypermobility syndrome patients versus 30 controls, with 27 patients and 21 controls undergoing autonomic testing. Orthostatic hypotension, POTS or uncategorised orthostatic intolerance in 78% (21/27) of patients versus 10% (2/21) of controls; heightened alpha- and beta-adrenergic responsiveness. Concludes dysautonomia is an extra-articular manifestation of joint hypermobility. Note: this study did not examine ME/CFS cohorts or mast cell activation.]

[55] Hvidberg MF, Brinth LS, Olesen AV, Petersen KD, Ehlers L. "The Health-Related Quality of Life for Patients with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)." PLOS ONE. 2015;10(7):e0132421. doi:10.1371/journal.pone.0132421. [ME/CFS had the lowest unadjusted EQ-5D-3L HRQoL of 20 compared conditions, worse than multiple sclerosis and stroke. Unadjusted mean 0.47 versus a general population mean of 0.85.]

[56] Eaton-Fitch N, Johnston SC, Zalewski P, Staines D, Marshall-Gradisnik S. "Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study." Quality of Life Research. 2020;29(6):1521-1531. doi:10.1007/s11136-019-02411-6

[57] Systematic review: "Health-related quality of life in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post COVID-19 Condition." Journal of Translational Medicine. 2025;23. doi:10.1186/s12967-025-06131-z. [All HRQoL domains consistently compromised; ME/CFS and long COVID among most disabling chronic conditions measured.]

[58] Pheby DFH, Araja D, Berkis U, et al. "The Development of a Consistent Europe-Wide Approach to Investigating the Economic Impact of Myalgic Encephalomyelitis (ME/CFS): A Report from the European Network on ME/CFS (EUROMENE)." Healthcare (Basel). 2020;8(2):88. doi:10.3390/healthcare8020088. [~2 million patients estimated in Europe; ~€40bn economic burden.]

[59] ME/CFS Research Foundation / Risklayer. "The rising cost of Long COVID and ME/CFS in Germany." Published 12 May 2025. mecfs-research.org. [>650,000 ME/CFS patients in Germany; German Federal Ministry of Health funding ~€150M through 2028.]

[60] ZonMw (Netherlands Organisation for Health Research and Development). ME/CFS Research Programme, €32.9M over 2021-2031, with €28.5M in awards announced April 2023. Referenced in Technology Networks (2024): technologynetworks.com

[61] Estevez-Lopez F, Mudie K, Wang-Steverding X, Bakken IJ, Ivanovs A, et al. "Systematic Review of the Epidemiological Burden of ME/CFS Across Europe (EUROMENE)." Journal of Clinical Medicine. 2020;9(5):1557. doi:10.3390/jcm9051557. [European prevalence 0.1-2.2%; major data gaps noted.]

[62] European ME Alliance (EMEA). "Pan-European ME Patient Survey Report." April 2024. 11,000+ respondents across Europe. europeanmealliance.org

[63] European Parliament. "Commission support for the Member States on ME/CFS research, data collection and medical education." Parliamentary Question E-003626/2025. September 2025. europarl.europa.eu

[64] Stanford ME/CFS Collaborative Research Center. "ME/CFS Collaborative Research Center." Stanford University. med.stanford.edu

[65] Montoya JG, Holmes TH, Anderson JN, et al. "Cytokine signature associated with disease severity in chronic fatigue syndrome patients." Proceedings of the National Academy of Sciences. 2017;114(34):E7150-E7158. doi:10.1073/pnas.1710519114

[66] Stanford ME/CFS Initiative. "Patient Care" and "About Us" pages. med.stanford.edu/chronicfatiguesyndrome. [Describes a multi-modality approach including medications, behavioural modifications and dietary changes, and defines pacing as breaking activities into smaller steps to avoid PEM. Note: these pages make no statement about graded exercise therapy.]

[67] Konig RS, Paris DH, Sollberger M, Tschopp R. "Identifying the mental health burden in ME/CFS patients in Switzerland: A pilot study." Heliyon. 2024;10(5):e27031. doi:10.1016/j.heliyon.2024.e27031. PMID: 38434357. PMC10907781. [88.2% negative mental health impact; 39.3% suicidal thoughts; 89.5% cited "told disease was psychosomatic" as trigger for suicidal ideation.]

[68] Psychiatry Advisor / Johnson SK, PhD (University of North Carolina Charlotte). "Addressing Depression in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome." Interview-based feature. [Prevalence 5-80% range due to coding assumptions; overlapping somatic symptoms vs. psychiatric attribution.]

[69] Hawk C, Jason LA, Torres-Harding S. "Differential diagnosis of chronic fatigue syndrome and major depressive disorder." International Journal of Behavioral Medicine. 2006;13(3):244-251. doi:10.1207/s15327558ijbm1303_8. [Depression: no PEM, exercise improves mood; ME/CFS: PEM present, exercise worsens function; cortisol patterns distinct. See also Health Rising / DePaul University summaries of Jason's differential-diagnosis work at healthrising.org.]

[70] Multiple sources on neural retraining programs: (a) Novella S. "Dynamic Neural Retraining." Science-Based Medicine, 6 February 2013; and Tuller D. "Trial By Error: What Is the Dynamic Neural Retraining System?" Virology Blog, 2 September 2020. (b) UK Advertising Standards Authority findings on Gupta Program and Lightning Process (ASA 2018). (c) Shepherd C, ME Association. Medical Adviser statements. (d) NICE NG206 (2021), recommendation 1.12.27: "Do not offer the Lightning Process, or therapies based on it, to people with ME/CFS." [See reference 37.]

[71] Bratty AJ. "Neuroplasticity Intervention, Amygdala and Insula Retraining (AIR), Significantly Improves Overall Health and Functioning Across Various Chronic Conditions." Integrative Medicine: A Clinician's Journal. 2024;22(6):20. [Self-selected customer survey; significant self-selection bias; participants recruited from Gupta Program's own database.]

[72] "13-year-old attempted suicide after Lightning Process course." Multiple Chemical Sensitivity blog, citing Norwegian media. 2012. [Documents psychological harm when programs blame patient non-recovery on insufficient effort or belief.]

[73] Wormser GP, Dattwyler RJ, Shapiro ED, et al. "The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America." Clinical Infectious Diseases. 2006;43(9):1089-1134. doi:10.1086/508667. [IDSA guidelines do not support IGeneX over standard two-tier testing for clinical decision-making; extended testing validity for clinical use remains contested.]

[74] ME/CFS Research Foundation. "International Declaration in Support of Research and Drug Development for ME/CFS and Long COVID." May 12, 2025. Signed by 65+ researchers and medical professionals from 14 countries. Published through International ME/CFS Conference Berlin 2025. mecfs-research.org

[75] Dorczok MC, Mittmann G, Mossaheb N, et al. "Dietary Supplementation for Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - A Systematic Review." Nutrients. 2025;17(3):475. doi:10.3390/nu17030475. PMID: 39940333. PMC11819863. [14 studies, n=809; L-carnitine+GAA, oxaloacetate, CoQ10-selenium, NADH-CoQ10 showed significant fatigue reductions; high risk of bias overall.]

[76] ConsumerLab.com. "CoQ10 and Ubiquinol Supplements Review." April 2024 (updated). [Independent testing of 20 CoQ10 products; brands passing testing include Qunol Ultra, Life Extension Super Ubiquinol, Jarrow Formulas QH-absorb, Doctor's Best with BioPerine; Kaneka QH identified as most clinically studied ubiquinol raw material.] consumerlab.com

[77] American ME and CFS Society. "Overlapping Conditions." ammes.org. [Documents comorbidities including Hashimoto's (20% in Richardson cohort), Sjogren's, autoimmune diseases, GI conditions, pain syndromes.] ammes.org

[78] Lossio-Ventura JA, Bian J, et al. "Digital health app data reveals an effect of ovarian hormones on long COVID and myalgic encephalomyelitis symptoms." medRxiv preprint. January 2025. doi:10.1101/2025.01.24.25321092. [948 Visible app users; all menstrual cycle phases showed significant symptom differences; menstrual phase worst; combined hormonal contraception associated with lower symptom burden.]

[79] Surviving Mold (survivingmold.com). Practitioner certification programme, patient membership, proprietary testing and legal/expert-witness resources. survivingmold.com. [Primary commercial source documenting the revenue streams described. Not peer-reviewed and cited only as evidence that these programmes exist. Regulatory history, including the 2013 Maryland Board of Physicians finding, is a matter of public record.]

[80] Thomas N, Gurvich C, Huang K, Gooley PR, Armstrong CW. "The underlying sex differences in neuroendocrine adaptations relevant to Myalgic Encephalomyelitis Chronic Fatigue Syndrome." Frontiers in Neuroendocrinology. 2022;66:100995. doi:10.1016/j.yfrne.2022.100995. PMID: 35421511. [Review of HPA, HPG and sex hormone dysregulation in ME/CFS; evidence for cortisol, estrogen, progesterone, aldosterone and DHEA abnormalities.]

[81] Khan M, Anees S, Anees MM, Chaudhry KK, Zaidi SMR, Das V, Rashid R. "Hormonal Fluctuations and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Women: The Role of Menstrual Cycle and Menopause." The Research of Medical Science Review. 2025;3(8). [Observational study of 150 women with ME/CFS: 90 premenopausal, 30 perimenopausal, 30 postmenopausal. Found a hormonal gradient across groups (ANOVA p<0.001), with lower estradiol and progesterone and higher gonadotropins at older reproductive age; lower estradiol and progesterone correlated with higher fatigue and pain. Note: published in a new, low-profile journal and not yet independently replicated.]

[82] Boneva RS, Maloney EM, Lin JM, Jones JF, Wieser F, Nater UM, Heim CM, Reeves WC. "Gynecological history in chronic fatigue syndrome: a population-based case-control study." Journal of Women's Health. 2011;20(1):21-28. doi:10.1089/jwh.2009.1900. See also Boneva RS, Lin JM, Unger ER. "Early menopause and other gynecologic risk indicators for chronic fatigue syndrome in women." Menopause. 2015;22(8):826-834. doi:10.1097/GME.0000000000000411. [CDC population-based case-control data, 84 CFS cases vs 73 controls: chronic pelvic pain 26.2% vs 2.7%; endometriosis 29.8% vs 12.3%; excessive menstrual bleeding 73.8% vs 42.5%. PCOS was not assessed in these analyses.]

[83] Huang K, de Sá AGC, Thomas N, Phair RD, Gooley PR, Ascher DB, Armstrong CW. "Discriminating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and comorbid conditions using metabolomics in UK Biobank." Communications Medicine. 2024;4:248. doi:10.1038/s43856-024-00669-7. PMCID:PMC11599898. [1,194 ME/CFS participants with plasma NMR metabolomics, compared against seven comorbid cohorts (hypertension, depression, asthma, IBS, hay fever, hypothyroidism, migraine) and 53,009 non-diseased controls.]

[84] Complex Chronic Illness Support (CCIS), New Zealand. "Skin and Temperature Support." March 2021. [Patient-support organisation resource, not peer reviewed. Summarises reported skin findings in ME/CFS including acne mechanisms (hormone fluctuation, stress hormones, reduced sunlight exposure) and altered skin sensation. Note: this document does not mention livedo reticularis. Cited here for description of reported manifestations, not for prevalence estimates.] ccisupport.org.nz

[85] Ali SA, Kheirabadi D. "Chronic Fatigue Syndrome." In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated December 13, 2025. Bookshelf ID: NBK557676. ncbi.nlm.nih.gov/books/NBK557676. [Clinical review documenting comorbid mood disorders, fibromyalgia and nociplastic pain, mast cell activation, orthostatic intolerance, sleep disorders and autoimmune rheumatological disease in ME/CFS.]

[86] D'Onghia M, Ciaffi J, Calabrese L, et al. "Fibromyalgia and Skin Disorders: A Systematic Review." Journal of Clinical Medicine. 2024;13(15):4404. doi:10.3390/jcm13154404. PMID: 39124671. PMC11312914.

[87] Mendias CL, Awan TM. "Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance." Sports Medicine. doi:10.1007/s40279-026-02437-0. Preprint posted 12 December 2025. [Google search trend analysis 2022-2025 showing rapid growth in BPC-157, TB-500, ipamorelin, MOTS-C, GHK-Cu searches; regulatory status overview.] doi: 10.20944/preprints202512.1011.v1

[88] McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing." Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. PMC12446177. doi:10.1007/s12178-025-09990-7. [Lee and Padgett retrospective n=16 knee study; Lee et al. 2024 bladder pilot n=12; Lee and Burgess 2025 first-in-human IV safety study n=2 healthy adults.]

[89] U.S. Anti-Doping Agency (USADA). "BPC-157: What Athletes Should Know About the Prohibited Experimental Peptide." usada.org. [BPC-157 not FDA-approved for human use; banned by WADA.] See also: Ortho and Wellness. "The Peptide Gamble: A Doctor's Warning on BPC-157 and TB-500." 2025. [TB-500 has zero human clinical trials; parent compound TB4 failed to publish Phase 2 results after 15+ years; 2024 study suggests TB-500 may not be the active compound.] usada.org

[90] Pilkington K, Ridge DT, Igwesi-Chidobe C, et al. "A relational analysis of an invisible illness: A meta-ethnography of people with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and their support needs." Social Science & Medicine. 2020;265:113369. doi:10.1016/j.socscimed.2020.113369. PMID: 33039734. [Meta-ethnography of 47 studies; invisibility, loss of self, fraught clinical encounters documented consistently; relational framework.]

[91] Fennell PA, Dorr N, George SS. "Elements of Suffering in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Experience of Loss, Grief, Stigma, and Trauma in the Severely and Very Severely Affected." Healthcare (Basel). 2021;9(5):553. PMC8150911. doi:10.3390/healthcare9050553. [Biographical disruption; cumulative grief; illness intrusiveness exceeds MS, laryngeal cancer, ESRD; trauma from stigmatization.]

[92] Tenhave A, Bognar R, Sidis A. "Into Adulthood with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis." Psychology, Health & Medicine. 2025;pages 1-19. doi:10.1080/13548506.2025.2495891. [Themes: independence inaccessible; "who could I have been?"; isolation and disconnection; "being with people but not being like them."]

[93] Psychology Today. "A Life Hijacked by Fatigue." March 14, 2025. psychologytoday.com. [Clinical review of ME/CFS psychological burden; biographical disruption; envy; medical gaslighting as routine experience.]

[94] Cairns R, Hotopf M. "A systematic review describing the prognosis of chronic fatigue syndrome." Occupational Medicine. 2005;55(1):20-31. doi:10.1093/occmed/kqi013. PMID: 15699087. [28 studies; median full recovery rate 5% (range 0-31%); median improvement 39.5% (range 8-63%); predictors of better outcome were less fatigue severity at baseline, a sense of control over symptoms, and not attributing the illness to a physical cause.]

[95] Hasan Z, Kuyvenhoven C, Chowdhury M, et al. "Patient perspectives of recovery from myalgic encephalomyelitis/chronic fatigue syndrome: An interpretive description study." Journal of Evaluation in Clinical Practice. 2024;30(2):234-242. doi:10.1111/jep.13938. PMID: 37927138. [33 interviews; 26 partial recovery, 7 full recovery; patients constructed individualized treatment plans without medical guidance; most full recovery accounts attributed to mind-body approaches - authors note this warrants cautious interpretation.]

[96] Saugstad OD, et al. "Specialised care for severely affected ME/CFS patients." Fatigue: Biomedicine, Health & Behavior. 2026;14(1):61-73, published online October 2025. doi:10.1080/21641846.2025.2565101. [Røysumtunet ME/CFS unit Norway; 24 severely ill patients 2021-2024; some achieved improvement in NICE severity classification with pacing-based specialist care.] See also: daratumumab pilot trial results: 2025 ME/CFS Science annual review. mecfsscience.org/2025-looking-back-on-a-year-of-me-cfs-research/ [10 female ME/CFS patients; 6 showed substantial clinical improvements; RESETME randomized trial initiated.]

[97] Sebring JCH. "Towards a sociological understanding of medical gaslighting in western health care." Sociology of Health & Illness. 2021;43(9):1951-1964. doi:10.1111/1467-9566.13367. [Foundational sociological account of medical gaslighting as invalidation, dismissal and inadequate care rooted in embedded and largely unchallenged clinical ideologies.]

[98] Thoma M, et al. "Why the Psychosomatic View on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Is Inconsistent with Current Evidence and Harmful to Patients." Medicina (Kaunas). 2024;60(1):83. PMC10819994. doi:10.3390/medicina60010083. [Comprehensive evidence review; psychosomatic model inconsistent with biological data; documents harm from misattribution; cognitive-behavioral model contributes to stigmatization.]

[99] Wikipedia contributors. "Controversies related to ME/CFS." Wikipedia. [Documents: diagnosis takes 5+ years; forced psychiatric hospitalization cases including Sophia Mirza; UK Parliamentary Group 2006 noting DWP/insurer financial interest in psychosocial classification; "a third to a half of all GPs did not accept ME/CFS as a genuine clinical entity" per 2020 literature review.] wikipedia.org

[100] The EDS Clinic. "Medical Gaslighting in Chronic Illness." eds.clinic. [ME/CFS patients wait average of 14 years for diagnosis per some sources; clinician-associated trauma comparable to PTSD; racial and intersectional dimensions documented.] eds.clinic

[101] Au L, Capotescu C, Eyal G, Finestone G. "Long Covid and Medical Gaslighting: Dismissal, Delayed Diagnosis, and Deferred Treatment." SSM - Qualitative Research in Health. 2022;2:100167. PMC9448633. doi:10.1016/j.ssmqr.2022.100167. [US survey n=334 long COVID patients; gaslighting framing prevalent; symptoms attributed to anxiety, "women's troubles," menopause; female respondents report more negative encounters.]

[102] ME Research UK. "Research shows that ME/CFS is a biological illness - so why do some people still think it is psychological in nature?" meresearch.org.uk. January 2024. [Summary of Thoma et al. 2024; psychosomatic misconception has impeded biomedical research and led to harm including misdiagnosis, delays, and dismissal.] meresearch.org.uk

[103] Dooley M, Vukelic A, Jim L. "Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment." Annals of Medicine and Surgery. 2024;86(12):7248-7254. doi:10.1097/MS9.0000000000002718. PMC11623837. [Literature review; Shoemaker Protocol was the only CIRS treatment with documented clinical efficacy in 11 of 13 articles; authors note competing interests as expert witnesses in CIRS cases.]

[104] Shoemaker RC. Overview of CIRS and the biotoxin pathway. Survivingmold.com documentation; Shoemaker RC, Johnson K, Jim L, et al. "Diagnostic process for CIRS: a consensus statement report." Internal Medicine Review. 2018;4(5). [24% of population HLA-susceptible to mold biotoxin illness; 13 symptom clusters; biomarker panel including MSH, C4a, TGF-beta-1, VEGF, MMP-9, VIP, HLA; HERTSMI-2 building testing.] See also: ScienceInsights.org review of CIRS evidence (March 2026): scienceinsights.org

[105] CDC MMWR. "Notes from the Field: Use of Unvalidated Urine Mycotoxin Tests for the Clinical Diagnosis of Illness - United States, 2014." MMWR Morbidity and Mortality Weekly Report. 2015;64(6):157, published February 20, 2015. [Case report of workplace mold scare driven by unvalidated urine mycotoxin test; no mold found; $25,000+ remediation cost; CDC statement that urine mycotoxin tests are not FDA-approved and that low-level mycotoxins from food are detectable in healthy persons.] cdc.gov See also: Hardin BD, Kelman BJ, Saxon A. "Adverse human health effects associated with molds in the indoor environment." J Occup Environ Med. 2003;45(5):470-8. And: Brewer JH, Thrasher JD, Straus DC, Madison RA, Hooper D. "Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome." Toxins. 2013;5(4):605-617. doi:10.3390/toxins5040605 (104 of 112 CFS patients tested positive for at least one urinary mycotoxin versus 0 of 55 controls; cited here for comparison, noting the study's in-house reference ranges and limited external validation).

[106] World Health Organization. "WHO Guidelines for Indoor Air Quality: Dampness and Mould." Geneva: WHO Regional Office for Europe; 2009. ISBN 9789289041683. [Residential dampness associated with current asthma at an odds ratio of 1.6 (95% CI 1.3-1.9), and with approximately 30-50% increases in a range of respiratory and asthma-related outcomes; WHO/Europe reported occupants of damp buildings have up to a 75% greater risk of respiratory symptoms; primary effects are respiratory, allergic, and immune perturbation; moisture control is the primary recommended intervention.] ncbi.nlm.nih.gov/books/NBK143941

[107] International Society for Environmentally Acquired Illness (ISEAI). iseai.org. [Nonprofit professional medical society; ~350 clinicians; functional medicine and root-cause approach to mold illness and environmentally acquired illness; publishes Mold Testing Guide, Binder Compendium; maintains provider directory at iseai.org/get-help; does not rigidly require Shoemaker Protocol; broader than CIRS framework.]

[108] World Health Organization. International Classification of Diseases. ICD-8 (1969); ICD-10 (G93.3); ICD-11 (8E49). [The WHO has classified myalgic encephalomyelitis as a neurological disease continuously since ICD-8 in 1969, where "encephalomyelitis ... (myalgic, benign)" was listed under code 323, inflammatory diseases of the central nervous system, in Chapter VI, Diseases of the Nervous System and Sense Organs. ICD-10 indexes both ME and CFS to G93.3, post-viral fatigue syndrome, in the nervous system chapter; ICD-11 uses 8E49, post-viral fatigue syndrome, with myalgic encephalomyelitis and chronic fatigue syndrome as inclusion terms. Separately, the US clinical modification ICD-10-CM introduced a dedicated code, G93.32, myalgic encephalomyelitis/chronic fatigue syndrome, effective October 1, 2022.] icd.who.int

[109] Holmes GP, Kaplan JE, Gantz NM, et al. "Chronic fatigue syndrome: a working case definition." Annals of Internal Medicine. 1988;108(3):387-389. doi:10.7326/0003-4819-108-3-387. PMID: 2829679. [The CDC working group publication that introduced the term "chronic fatigue syndrome," roughly three decades after "benign myalgic encephalomyelitis" entered use and 19 years after the WHO classified ME as a neurological disease. The group selected the new name as more neutral and inclusive while acknowledging that myalgic encephalomyelitis was the more accepted term internationally.] pubmed.ncbi.nlm.nih.gov/2829679

[110] Montoya JG, Dowell TG, Mooney AE, Dimmock ME, Chu L. "Caring for the Patient with Severe or Very Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome." Healthcare (Basel). 2021;9(10):1331. doi:10.3390/healthcare9101331. PMID: 34683011. PMC8544443. [Clinical guidance for severe ME/CFS: interact at the patient's pace, time of day and length of time they can manage; involve the caregiver to conserve patient energy; creative approaches may be needed where the patient's ability to speak is limited.]

[111] Kingdon C, Giotas D, Nacul L, Lacerda E. "Health Care Responsibility and Compassion: Visiting the Housebound Patient Severely Affected by ME/CFS." Healthcare (Basel). 2020;8(3):197. doi:10.3390/healthcare8030197. PMC7551603. [Questions should be simple and require short answers; patients may be so wary of PEM that they are fearful of articulating what they need; the effort patients make to prepare for a visit is never witnessed by the provider.]

[112] van Campen CLMC, Verheugt FWA, Rowe PC, Visser FC. "Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: A quantitative, controlled study using Doppler echography." Clinical Neurophysiology Practice. 2020;5:50-58. doi:10.1016/j.cnp.2020.01.003. PMID: 32140630. [429 ME/CFS patients versus 44 healthy controls. Mean cerebral blood flow reduction at end-tilt was 26% in patients versus 7% in controls (24% in those with a normal heart rate and blood pressure response, 28% with delayed orthostatic hypotension, 29% with POTS). Using a cutoff of 13%, two standard deviations below normal, 90% of all patients showed an abnormal reduction, including 82% of the 247 patients whose heart rate and blood pressure responses were entirely normal. Measured by extracranial Doppler echography, not SPECT.]